Skip to main content

Table 6 Investigator assessed best overall response

From: EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex

Best response according to medical judgment Everolimus
(N = 120), n (%)
Complete response 0 (0.0)
Partial response 81 (67.5)
Stable disease 35 (29.2)
Progressive disease 1 (0.8)
Unknown 3 (2.5)